Insider Selling: Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells $24,800.00 in Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma sold 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $12.40, for a total transaction of $24,800.00. Following the completion of the sale, the president now directly owns 2,920,467 shares of the company’s stock, valued at approximately $36,213,790.80. This represents a 0.07 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Songjiang Ma also recently made the following trade(s):

• On Monday, January 6th, Songjiang Ma sold 941 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.16, for a total value of $9,560.56.
• On Monday, December 30th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.50, for a total transaction of $25,000.00.
• On Thursday, December 26th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.70, for a total transaction of $25,400.00.
• On Monday, December 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.27, for a total transaction of $24,540.00.
• On Thursday, December 19th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.82, for a total value of $21,640.00.
• On Tuesday, December 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.05, for a total transaction of $22,100.00.

Gyre Therapeutics Trading Down 3.7 %

Shares of GYRE opened at $9.62 on Thursday. Gyre Therapeutics, Inc. has a 52-week low of $8.26 and a 52-week high of $27.10. The stock has a 50 day simple moving average of $12.20 and a 200 day simple moving average of $12.65.

Institutional Investors Weigh In On Gyre Therapeutics

Several large investors have recently made changes to their positions in GYRE. Charles Schwab Investment Management Inc. boosted its stake in Gyre Therapeutics by 392.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company’s stock worth $1,425,000 after purchasing an additional 90,557 shares during the period. Geode Capital Management LLC boosted its position in shares of Gyre Therapeutics by 16.9% during the third quarter. Geode Capital Management LLC now owns 303,647 shares of the company’s stock worth $3,808,000 after buying an additional 43,840 shares during the period. Advantage Alpha Capital Partners LP acquired a new position in shares of Gyre Therapeutics during the third quarter worth about $334,000. WINTON GROUP Ltd bought a new position in shares of Gyre Therapeutics during the second quarter worth about $220,000. Finally, Bank of New York Mellon Corp bought a new stake in Gyre Therapeutics in the 2nd quarter valued at approximately $218,000. Institutional investors own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.